Travere Therapeutics, Inc.·4

Feb 3, 9:30 PM ET

Inrig Jula 4

4 · Travere Therapeutics, Inc. · Filed Feb 3, 2026

Research Summary

AI-generated summary of this filing

Updated

Travere (TVTX) CMO Inrig Jula Sells Shares, Receives RSU Award

What Happened
Inrig Jula, Chief Medical Officer of Travere Therapeutics (TVTX), had a sell-to-cover sale and received equity awards. On 2026-01-31 Jula had 28,130 restricted stock units settle (acquired at $0.00) and was also granted/received 75,000 derivative awards (reported as $0.00). On 2026-02-03 Jula sold 6,956 shares in an open-market transaction at $32.12 per share for proceeds of $223,427. The sale was executed to satisfy tax withholding obligations related to the RSU settlement (see footnote).

Key Details

  • Transaction dates: RSU settlement/grant on 2026-01-31; sale executed 2026-02-03. Filing accession: 0001902368-26-000003.
  • Sale details: 6,956 shares sold at $32.12 each, total proceeds $223,427.
  • Awards received: 28,130 RSUs settled; 75,000 derivative awards (RSUs/options depending on plan) granted at $0.00.
  • Footnotes: F1 = each RSU converts to one share upon settlement; F2 = the sale was a mandatory "sell-to-cover" to fund tax withholding (not a discretionary sale by the insider); F3 = standard vesting schedule noted (one-fourth after 1 year, then monthly over 36 months) for stock option-style awards.
  • Shares owned after transaction: not specified in the provided filing.
  • Timeliness: Filing was submitted 2026-02-03 for transactions dated 2026-01-31 — appears to be timely (Form 4 is due within two business days).

Context
The RSU settlement and grant reflect compensation; the sale was a routine sell-to-cover to satisfy tax withholding and therefore does not necessarily indicate a voluntary decision to liquidate holdings. For retail investors, such mandated sales are common following equity compensation events and differ from discretionary insider selling.

Insider Transaction Report

Form 4
Period: 2026-01-31
Inrig Jula
CHIEF MEDICAL OFFICER
Transactions
  • Award

    Common Stock

    [F1]
    2026-01-31+28,130114,441 total
  • Sale

    Common Stock

    [F2]
    2026-02-03$32.12/sh6,956$223,427107,485 total
  • Award

    Employee stock option (right to buy)

    [F3]
    2026-01-31+75,00075,000 total
    Exercise: $33.09Exp: 2036-01-31Common Stock (75,000 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
  • [F2]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
  • [F3]One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact|2026-02-03

Documents

1 file
  • 4
    form4-02032026_090210.xmlPrimary